EGFR and non-small cell lung carcinoma: For patients with EGFR mutant non-small cell lung cancer (NSCLC), several trials have consistently demonstrated EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, afatinib and icotinib can result in better outcomes than standard platinum-based chemotherapy [1-4].